title: Croxatto's fifty-year pursuit: from pepsanurin to the discovery of a new kininogen-derived peptide (PU-D1).
abstract: This paper narrates Dr Héctor R Croxatto and collaborators' efforts over the past 50 years in search for peptidic hormones obtained by pepsin hydrolysis of blood plasma substrates. In the forties, Croxatto described three peptidic fractions characterized by their hypertensive, oxytocic and antidiuretic properties, designated as pepsitensin, pepsitocin and pepsanurin, respectively. While pepsitensin and pepsitocin were later identified as angiotensin I and metlys-bradykinin, pepsanurin was not identified and its research was halted for 35 years. During that time, Prof Croxatto and his group worked mostly on the renal kallikrein-kinin system, studying its physiological anti-hypertensive role, making significant contributions in the field of renovascular hypertension. After the discovery of atrial natriuretic peptide, Croxatto resumed his work with pepsanurin. In a series of papers from 1988 to 1998, it was shown that: 1) when injected intraperitoneally or in the intestinal lumen of anesthetized rats, or in the isolated perfused rat kidneys, pepsanurin is a potent inhibitor of the natriuretic effect of ANP; 2) plasma kininogens are identified as the substrates for pepsanurin formation; 3) bradykinin and prokinins exert the anti-ANP effect when injected either intravenously, intraperitoneally or intraduodenally, at small non-vasodilator doses; endogenous kinins also block ANP renal excretory effects; 4) a 20-amino acid peptide released by pepsin from domain 1 of purified LMW kininogen was isolated by Croxatto and collaborators, designed as PU-D1, and shown to exert similar anti-ANP effects as pepsanurin or kinins, but being more potent and longer lasting; 5) the anti-ANP effect of pepsanurin, kinins and PU-D1 is mediated by B2 kinin receptors, since it is blocked by a bradykinin receptor antagonist. Currently, Dr Croxatto is working on the hypothesis that intestinal-borne kinins and/or PU-D1 may reduce renal excretion during the prandial cycle.
authors.affiliation: Departamento de Ciencias Fisiológicas, Facultad de Ciencias Biológicas, Pontificia Universidad Católica de Chile, Santiago, Chile. mboric@genes.bio.puc.cl
authors.forename: M P
authors.initials: MP
authors.lastname: Boric
authors.forename: X F
authors.initials: XF
authors.lastname: Figueroa
authors.forename: R
authors.initials: R
authors.lastname: Albertini
authors.forename: J S
authors.initials: JS
authors.lastname: Roblero
mesh_terms: D000818:Animals; D009320:Atrial Natriuretic Factor; D015853:Cysteine Proteinase Inhibitors / Q000494:pharmacology; D036341:Intercellular Signaling Peptides and Proteins; D007413:Intestinal Mucosa / Q000378:metabolism; D007610:Kallikreins; D007668:Kidney / Q000378:metabolism; D007704:Kininogens / Q000494:pharmacology; D007705:Kinins; D010434:Pepsin A; D010446:Peptide Fragments / Q000494:pharmacology; D010455:Peptides / Q000494:pharmacology; D051381:Rats
chemical_list: D015853:Cysteine Proteinase Inhibitors; D036341:Intercellular Signaling Peptides and Proteins; D007704:Kininogens; D007705:Kinins; C117937:PU-D1 peptide; D010446:Peptide Fragments; D010455:Peptides; C058006:pepsanurin; D009320:Atrial Natriuretic Factor; D007610:Kallikreins; D010434:Pepsin A